Nanomedicine holds great potential for targeted drug delivery, diagnostic imaging, and regenerative medicine. However, clinical translation of nanomedicine technologies faces significant hurdles. These include the scalability of manufacturing processes, potential immunogenicity, and the complexity of biological interactions at the nanoscale. Furthermore, patient-specific customization and the high cost of development are major obstacles that need to be addressed.
